ArticleScientific reports2020
Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Development and application of the direct mycobacterial growth inhibition assay: a systematic review.Frontiers in immunology · 2024Pooled it
- Functional and phenotypic characterization of peripheral blood mononuclear cells from tuberculosis patients in Southern Thailand.Frontiers in immunology · 2025Article
- Recombinant BCG vaccine expressing multistage antigens ofHuman vaccines & immunotherapeutics · 2024Article
- A modified mycobacterial growth inhibition assay for the functional assessment of vaccine-mediated immunity.NPJ vaccines · 2024Article
- The chosen few:Frontiers in immunology · 2024Review
- Mucosal BCG delivery provides a spectrum of protection from differentFrontiers in tuberculosis · 2024Article
- Galleria mellonella-intracellular bacteria pathogen infection models: the ins and outs.FEMS microbiology reviews · 2023Review
- Efficacy and immunogenicity of different BCG doses in BALB/c and CB6F1 mice when challenged with H37Rv or Beijing HN878.Scientific reports · 2021Article
- A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates.NPJ vaccines · 2021Article
- TheF1000Research · 2021Article
- Innate Immune Responses ofFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In the absence of a correlate(s) of protection against human tuberculosis and a validated animal model of the disease, tools to facilitate vaccine development must be identified. We present an optimised ex vivo mycobacterial growth inhibition assay (MGIA) to assess the ability of host cells within the lung to inhibit mycobacterial growth, including Bacille Calmette-Guérin (BCG) and Mycobacterium tuberculosis (MTB) Erdman. Growth of BCG was reduced by 0.39, 0.96 and 0.73 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.